TARIS ^® to Present at Cowen Health Care Conference

LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS announced that CEO Purnanand Sarma is presenting today, March 12^th, at the Cowen and Company 38th Annual Health Care Conference from 8:30-8:55 a.m. ET in the Northeastern Room, 3^rd floor at the Boston Marriott Copley Place.

About TARIS Biomedical^®

TARIS Biomedical^® is building a unique therapeutically-focused urology company, developing targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www.tarisbiomedical.com

Recent Stories

• 
  TARIS Presents Data Demonstrating Significant Local and Systemic Immune Modulation Following Continuous Low-Dose Bladder Delivery of Gemcitabine
  April 16, 2018
  LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today presented a late-breaking poster titled “Significant cytotoxic and immunomodulatory effects of continuous low-dose intravesical gemcitabin... more »
• 
  TARIS® Announces Late-Breaking Poster Presentation at American Association of Cancer Research Annual Meeting
  April 09, 2018
  LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today announced that it will present a late-breaking poster related to TAR-200 (GemRIS™), the company’s lead clinical program in bladder cancer,... more »
• 
  U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer
  April 03, 2018
  LEXINGTON, Mass.--(EON: Enhanced Online News)--TARIS today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for TAR-200 (GemRIS™) for the treat... more »

More Stories